Published sensitization studies report rates below 1% in patch testing panels, and no carcinogenic or reproductive toxicity signals have emerged in long-term surveillance data
Inflammatory bowel conditions, leaky gut syndrome, and other gastrointestinal issues may respond to BPC-157's protective and healing effects
Importantly, tirzepatide shows preferential potency at GIPR relative to GLP-1R, which is one reason its metabolic effect profile differs from GLP-1 mono-agonists such as semaglutide
When used long-term, tesamorelin is primarily beneficial for reducing visceral fat but may require ongoing use to maintain results, as fat accumulation can return after discontinuation
It is more likely to cause safety problems based on excessive doses or unmonitored injectable intake, rather than the daily supplementation
Category 3 nominated without adequate support